On the public citation graph

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

https://doi.org/10.1056/nejmoa1615758
0 signed · 1007 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.amjcard.2016.10.037openalex-snapshot
Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial
inferredcites →https://doi.org/10.1016/j.cca.2014.02.018openalex-snapshot
LDL cholesterol performance of beta quantification reference measurement procedure
inferredcites →https://doi.org/10.1016/j.cell.2009.01.035openalex-snapshot
Origins and Mechanisms of miRNAs and siRNAs
inferredcites →https://doi.org/10.1016/j.cell.2015.01.036openalex-snapshot
A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
inferredcites →https://doi.org/10.1016/j.jacc.2015.02.017openalex-snapshot
Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes
inferredcites →https://doi.org/10.1016/s0140-6736(10)60284-xopenalex-snapshot
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(10)60308-xopenalex-snapshot
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
inferredcites →https://doi.org/10.1038/nature02872openalex-snapshot
Revealing the world of RNA interference
inferredcites →https://doi.org/10.1038/nrg3978openalex-snapshot
Knocking down disease: a progress report on siRNA therapeutics
inferredcites →https://doi.org/10.1056/nejmoa054013openalex-snapshot
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
inferredcites →https://doi.org/10.1056/nejmoa1500858openalex-snapshot
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
inferredcites →https://doi.org/10.1056/nejmoa1501031openalex-snapshot
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
inferredcites →https://doi.org/10.1056/nejmoa1609243openalex-snapshot
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
inferredcites →https://doi.org/10.1056/nejmoa1615664openalex-snapshot
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
inferredcites →https://doi.org/10.1056/nejmp068242openalex-snapshot
Exploring the Uses of RNAi — Gene Knockdown and the Nobel Prize
inferredcites →https://doi.org/10.1093/eurheartj/ehw046openalex-snapshot
Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents
inferredcites →https://doi.org/10.1161/circulationaha.116.025080openalex-snapshot
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
inferredcites →https://doi.org/10.1161/circulationaha.116.025253openalex-snapshot
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
inferredcites →https://doi.org/10.7326/0003-4819-158-7-201304020-00004openalex-snapshot
Discontinuation of Statins in Routine Care Settings

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4623114openalex-extracted
inferred← citeshttps://doi.org/10.1001/jama.2021.17980openalex-snapshot
Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk—Reply
inferred← citeshttps://doi.org/10.1001/jamacardio.2017.2288openalex-snapshot
Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk
inferred← citeshttps://doi.org/10.1001/jamacardio.2018.2866openalex-snapshot
Association of Genetically Enhanced Lipoprotein Lipase–Mediated Lipolysis and Low-Density Lipoprotein Cholesterol–Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes
inferred← citeshttps://doi.org/10.1001/jamacardio.2019.3502openalex-snapshot
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
inferred← citeshttps://doi.org/10.1001/jamacardio.2019.3528openalex-snapshot
Safety and Tolerability of Sustained Lipid-Lowering Therapy
inferred← citeshttps://doi.org/10.1001/jamacardio.2024.1659openalex-snapshot
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease
inferred← citeshttps://doi.org/10.1002/adma.202003537openalex-snapshot
A Versatile Nonviral Delivery System for Multiplex Gene‐Editing in the Liver
inferred← citeshttps://doi.org/10.1002/advs.202105126openalex-snapshot
CRISPR/Cas9 Screens Reveal that Hexokinase 2 Enhances Cancer Stemness and Tumorigenicity by Activating the ACSL4‐Fatty Acid β‐Oxidation Pathway
inferred← citeshttps://doi.org/10.1002/ajh.27015openalex-snapshot
SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers
inferred← citeshttps://doi.org/10.1002/alz.13703openalex-snapshot
Silencing Apoe with divalent‐siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/btm2.10086openalex-snapshot
RNA‐Peptide nanoplexes drug DNA damage pathways in high‐grade serous ovarian tumors
inferred← citeshttps://doi.org/10.1002/cam4.6310openalex-snapshot
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials
inferred← citeshttps://doi.org/10.1002/cbic.202500972openalex-snapshot
Enzyme‐Assisted Synthesis and In Vitro Characterization of Bifunctional PCSK9 Inhibitors
inferred← citeshttps://doi.org/10.1002/clc.23410openalex-snapshot
Management of LDL ‐cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers
inferred← citeshttps://doi.org/10.1002/cmdc.202000431openalex-snapshot
Exploring Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Autoproteolysis Process by Molecular Simulations: Hints for Drug Design
inferred← citeshttps://doi.org/10.1002/cpt.1110openalex-snapshot
Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases
inferred← citeshttps://doi.org/10.1002/cpt.1193openalex-snapshot
Adverse Events Associated With PCSK 9 Inhibitors: A Real‐World Experience
inferred← citeshttps://doi.org/10.1002/cpt.2774openalex-snapshot
Translational Population‐Pharmacodynamic Modeling of a Novel Long‐Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia
inferred← citeshttps://doi.org/10.1002/ejlt.201800029openalex-snapshot
Polyunsaturated Fatty Acids and Atherosclerosis: Insights from Pre‐Clinical Studies
inferred← citeshttps://doi.org/10.1002/hep.29478openalex-snapshot
A microRNA‐7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib‐resistant cells in human hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/hep4.1405openalex-snapshot
A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice
inferred← citeshttps://doi.org/10.1002/jcsm.12960openalex-snapshot
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
inferred← citeshttps://doi.org/10.1002/pdi.2333openalex-snapshot
Inclisiran
inferred← citeshttps://doi.org/10.1002/ped4.12004openalex-snapshot
RNAi technique, how far is it from pediatrics?
inferred← citeshttps://doi.org/10.1002/ped4.12018openalex-snapshot
Potential clinical application of RNA i‐based therapeutic strategies for treatment of chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/prp2.1080openalex-snapshot
The N‐Acetylgalactosamine ‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
inferred← citeshttps://doi.org/10.1002/tcr.202300018openalex-snapshot
Metal‐Organic Frameworks Nanocarriers for Functional Nucleic Acid Delivery in Biomedical Applications
inferred← citeshttps://doi.org/10.1002/wrna.1594openalex-snapshot
The powerful world of antisense oligonucleotides: From bench to bedside
inferred← citeshttps://doi.org/10.1007/164_2020_361openalex-snapshot
LDL-Cholesterol-Lowering Therapy
inferred← citeshttps://doi.org/10.1007/978-1-0716-2010-6_1openalex-snapshot
Introduction and History of the Chemistry of Nucleic Acids Therapeutics
inferred← citeshttps://doi.org/10.1007/978-1-0716-2010-6_25openalex-snapshot
Preclinical Safety Assessment of Therapeutic Oligonucleotides
inferred← citeshttps://doi.org/10.1007/978-3-030-00710-2_15openalex-snapshot
Oligonucleotides
inferred← citeshttps://doi.org/10.1007/978-3-030-19966-1_7openalex-snapshot
RNA Therapeutics: How Far Have We Gone?
inferred← citeshttps://doi.org/10.1007/978-3-030-36694-0_2openalex-snapshot
Diabetes and Dyslipidemia
inferred← citeshttps://doi.org/10.1007/978-3-030-43683-4_4openalex-snapshot
Current and Emerging Therapies for Atherosclerosis
inferred← citeshttps://doi.org/10.1007/978-3-030-56514-5_1openalex-snapshot
History of Lipidology
inferred← citeshttps://doi.org/10.1007/978-3-030-56514-5_12openalex-snapshot
Management of Statin Intolerance
inferred← citeshttps://doi.org/10.1007/978-3-030-56514-5_14openalex-snapshot
Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and Its Therapeutic Inhibition
inferred← citeshttps://doi.org/10.1007/978-3-030-56514-5_33openalex-snapshot
Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis
inferred← citeshttps://doi.org/10.1007/978-3-030-62080-6_13openalex-snapshot
Personalized Therapy of Cardiovascular Disorders
inferred← citeshttps://doi.org/10.1007/978-3-030-80100-7_7openalex-snapshot
Personalized Medicine’s Impact on Disease
inferred← citeshttps://doi.org/10.1007/978-3-030-92034-0_9openalex-snapshot
Long Noncoding RNAs as Therapeutic Targets
inferred← citeshttps://doi.org/10.1007/978-3-031-26681-2_27openalex-snapshot
Clinical Efficacy of Proprotein Convertase Synthase Kexin Type 9 Inhibition in Persons with Diabetes Mellitus
inferred← citeshttps://doi.org/10.1007/978-3-031-26681-2_30openalex-snapshot
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-031-75686-3_6openalex-snapshot
The Orchestra of Genetics: Genetic Predisposition to Metabolic Syndrome
inferred← citeshttps://doi.org/10.1007/978-3-031-82232-2_24openalex-snapshot
How to Evaluate and Reduce Micro- and/or Macrovascular Residual Risk?
inferred← citeshttps://doi.org/10.1007/978-3-319-27316-7_2-1openalex-snapshot
Diabetes and Dislipidemia
inferred← citeshttps://doi.org/10.1007/978-3-319-27316-7_2-2openalex-snapshot
Diabetes and Dyslipidemia
inferred← citeshttps://doi.org/10.1007/978-3-319-27316-7_2-3openalex-snapshot
Diabetes and Dyslipidemia
inferred← citeshttps://doi.org/10.1007/978-3-319-27316-7_2-4openalex-snapshot
Diabetes and Dyslipidemia
inferred← citeshttps://doi.org/10.1007/978-3-319-44433-8_2openalex-snapshot
Diabetes and Dislipidemia
inferred← citeshttps://doi.org/10.1007/978-981-15-1671-9_23openalex-snapshot
Small Interfering RNAs and RNA Therapeutics in Cardiovascular Diseases
inferred← citeshttps://doi.org/10.1007/978-981-15-1671-9_24openalex-snapshot
Prospective Advances in Non-coding RNAs Investigation
inferred← citeshttps://doi.org/10.1007/978-981-15-2517-9_8openalex-snapshot
Drug Discovery for Coronary Artery Disease
inferred← citeshttps://doi.org/10.1007/978-981-15-6082-8_9openalex-snapshot
Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism
inferred← citeshttps://doi.org/10.1007/978-981-16-3923-4_11openalex-snapshot
PCSK9 Inhibiting Monoclonal Antibodies
inferred← citeshttps://doi.org/10.1007/978-981-16-3923-4_12openalex-snapshot
PCSK9 Inhibiting siRNA
inferred← citeshttps://doi.org/10.1007/978-981-19-5642-3_10openalex-snapshot
Genome Editing in Dyslipidemia and Atherosclerosis
inferred← citeshttps://doi.org/10.1007/978-981-92-1034-3_11openalex-snapshot
Nanomaterials in Cardiovascular Applications
inferred← citeshttps://doi.org/10.1007/978-981-95-3957-4_24openalex-snapshot
RNA-Based Therapeutics
inferred← citeshttps://doi.org/10.1007/978-981-95-5378-5_10openalex-snapshot
RNAi in the Postgenomic Era: Delivery, Drug Design, and Emerging Technologies
inferred← citeshttps://doi.org/10.1007/978-981-96-3041-7_1openalex-snapshot
Historical Overview of RNA Therapeutics
inferred← citeshttps://doi.org/10.1007/978-981-96-3041-7_22openalex-snapshot
RNA Bioconjugation: Current Development in siRNA Therapeutics
inferred← citeshttps://doi.org/10.1007/978-981-96-3456-9_12openalex-snapshot
Practical Clinical Approaches Used in RNA-Based Therapeutics
inferred← citeshttps://doi.org/10.1007/s00059-022-05133-7openalex-snapshot
Lipidsenkung: neue Substanzen und neue Konzepte
inferred← citeshttps://doi.org/10.1007/s00108-020-00799-9openalex-snapshot
Update Lipidologie
inferred← citeshttps://doi.org/10.1007/s00108-023-01524-yopenalex-snapshot
Primäre Fettstoffwechselstörungen – Stellenwert in aktuellen Dyslipidämieleitlinien und therapeutische Innovationen
inferred← citeshttps://doi.org/10.1007/s00125-024-06100-zopenalex-snapshot
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
inferred← citeshttps://doi.org/10.1007/s00228-018-2453-1openalex-snapshot
Recent major advances in cardiovascular pharmacotherapy
inferred← citeshttps://doi.org/10.1007/s00228-021-03242-6openalex-snapshot
Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies
inferred← citeshttps://doi.org/10.1007/s00398-024-00650-5openalex-snapshot
Moderne Strategien zur Lipidsenkung – die frühe Kombinationstherapie
inferred← citeshttps://doi.org/10.1007/s00508-026-02760-6openalex-snapshot
Österreichischer Lipidkonsensus 2026
inferred← citeshttps://doi.org/10.1007/s10304-021-00418-2openalex-snapshot
Individuelle kardiovaskuläre Risiken der Patientin in der Lebensmitte
inferred← citeshttps://doi.org/10.1007/s10554-021-02164-9openalex-snapshot
Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease
inferred← citeshttps://doi.org/10.1007/s10557-019-06919-4openalex-snapshot
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
inferred← citeshttps://doi.org/10.1007/s10557-020-07017-6openalex-snapshot
Biotechnology Approaches for the Treatment of Dyslipidemia
inferred← citeshttps://doi.org/10.1007/s10557-020-07023-8openalex-snapshot
Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
inferred← citeshttps://doi.org/10.1007/s10557-021-07293-wopenalex-snapshot
Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review
inferred← citeshttps://doi.org/10.1007/s10557-024-07587-9openalex-snapshot
Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review
inferred← citeshttps://doi.org/10.1007/s11096-024-01784-0openalex-snapshot
Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database
inferred← citeshttps://doi.org/10.1007/s11427-022-2171-2openalex-snapshot
RNA therapeutics: updates and future potential
inferred← citeshttps://doi.org/10.1007/s11428-017-0233-7openalex-snapshot
Diabetes Update 2017 – Lipide
inferred← citeshttps://doi.org/10.1007/s11739-018-1810-5openalex-snapshot
Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist
inferred← citeshttps://doi.org/10.1007/s11739-026-04417-8openalex-snapshot
Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study
inferred← citeshttps://doi.org/10.1007/s11883-017-0684-8openalex-snapshot
PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies
inferred← citeshttps://doi.org/10.1007/s11883-018-0718-xopenalex-snapshot
Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
inferred← citeshttps://doi.org/10.1007/s11883-019-0778-6openalex-snapshot
Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/s11883-019-0813-7openalex-snapshot
Highlights from Selected Cardiovascular Disease Prevention Studies Presented at the 2019 European Society of Cardiology Congress
inferred← citeshttps://doi.org/10.1007/s11883-020-00844-wopenalex-snapshot
Clinical Pharmacology of Statins: an Update
inferred← citeshttps://doi.org/10.1007/s11883-020-00847-7openalex-snapshot
New Pharmacological Approaches to Target PCSK9
inferred← citeshttps://doi.org/10.1007/s11883-020-0826-2openalex-snapshot
Nucleic Acid–Based Therapies for Atherosclerosis
inferred← citeshttps://doi.org/10.1007/s11883-021-00936-1openalex-snapshot
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
inferred← citeshttps://doi.org/10.1007/s11883-021-00938-zopenalex-snapshot
Novel RNAi-Based Therapies for Atherosclerosis
inferred← citeshttps://doi.org/10.1007/s11883-022-01056-0openalex-snapshot
Inclisiran: How Widely and When Should We Use It?
inferred← citeshttps://doi.org/10.1007/s11883-022-01060-4openalex-snapshot
Lp(a): a New Pathway to Target?
inferred← citeshttps://doi.org/10.1007/s11883-023-01156-5openalex-snapshot
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
inferred← citeshttps://doi.org/10.1007/s11883-025-01280-4openalex-snapshot
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
inferred← citeshttps://doi.org/10.1007/s11886-018-0997-4openalex-snapshot
Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events
inferred← citeshttps://doi.org/10.1007/s11886-018-1068-6openalex-snapshot
Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies
inferred← citeshttps://doi.org/10.1007/s11886-019-1103-2openalex-snapshot
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
inferred← citeshttps://doi.org/10.1007/s11886-019-1128-6openalex-snapshot
Is There a Need to Revise Goals in the Management of Dyslipidemias?
inferred← citeshttps://doi.org/10.1007/s11886-019-1159-zopenalex-snapshot
New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/s11886-019-1160-6openalex-snapshot
Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
inferred← citeshttps://doi.org/10.1007/s11886-019-1161-5openalex-snapshot
Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
inferred← citeshttps://doi.org/10.1007/s11886-019-1175-zopenalex-snapshot
Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options
inferred← citeshttps://doi.org/10.1007/s11886-020-01427-6openalex-snapshot
Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
inferred← citeshttps://doi.org/10.1007/s11886-021-01514-2openalex-snapshot
Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias
inferred← citeshttps://doi.org/10.1007/s11886-022-01729-xopenalex-snapshot
SAMSON and the Nocebo Effect: Management of Statin Intolerance
inferred← citeshttps://doi.org/10.1007/s11886-022-01782-6openalex-snapshot
PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection
inferred← citeshttps://doi.org/10.1007/s11886-024-02028-3openalex-snapshot
Updates on Non-Statin LDL-Lowering Therapy
inferred← citeshttps://doi.org/10.1007/s11886-025-02329-1openalex-snapshot
Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations
inferred← citeshttps://doi.org/10.1007/s11892-017-0942-8openalex-snapshot
Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions
inferred← citeshttps://doi.org/10.1007/s11892-018-1087-0openalex-snapshot
Beyond Statins: Who and When to Prescribe?
inferred← citeshttps://doi.org/10.1007/s11936-019-0741-4openalex-snapshot
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
inferred← citeshttps://doi.org/10.1007/s12016-017-8611-xopenalex-snapshot
MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
inferred← citeshttps://doi.org/10.1007/s12170-019-0607-zopenalex-snapshot
Emerging Lipid-Lowering Therapies in Secondary Prevention
inferred← citeshttps://doi.org/10.1007/s12170-019-0627-8openalex-snapshot
A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients
inferred← citeshttps://doi.org/10.1007/s12170-022-00694-yopenalex-snapshot
New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention
inferred← citeshttps://doi.org/10.1007/s12265-020-09961-yopenalex-snapshot
Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments
inferred← citeshttps://doi.org/10.1007/s12265-025-10717-9openalex-snapshot
RNA Therapeutics in Heart Failure
inferred← citeshttps://doi.org/10.1007/s12272-019-01116-1openalex-snapshot
Current pharmacotherapies for atherosclerotic cardiovascular diseases
inferred← citeshttps://doi.org/10.1007/s12274-023-6238-5openalex-snapshot
RNA-based nanomedicines and their clinical applications
inferred← citeshttps://doi.org/10.1007/s12325-017-0586-8openalex-snapshot
Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
inferred← citeshttps://doi.org/10.1007/s12325-018-0716-yopenalex-snapshot
Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials
inferred← citeshttps://doi.org/10.1007/s12602-021-09798-0openalex-snapshot
In Vitro and In Vivo Cholesterol Reducing Ability and Safety of Probiotic Candidates Isolated from Korean Fermented Soya Beans
inferred← citeshttps://doi.org/10.1007/s12687-017-0316-6openalex-snapshot
Diversity and inclusion in genomic research: why the uneven progress?
inferred← citeshttps://doi.org/10.1007/s13167-017-0106-6openalex-snapshot
PCSK9 signaling pathways and their potential importance in clinical practice
inferred← citeshttps://doi.org/10.1007/s15027-020-3424-xopenalex-snapshot
Perspektiven neuer lipidsenkender Substanzen für die Praxis
inferred← citeshttps://doi.org/10.1007/s15027-024-3654-4openalex-snapshot
Homozygote familiäre Hypercholesterinämie - Teil 2
inferred← citeshttps://doi.org/10.1007/s40256-017-0259-7openalex-snapshot
Management of Statin Intolerance in 2018: Still More Questions Than Answers
inferred← citeshttps://doi.org/10.1007/s40256-018-0270-7openalex-snapshot
Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1007/s40256-018-0312-1openalex-snapshot
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
inferred← citeshttps://doi.org/10.1007/s40256-023-00568-7openalex-snapshot
Inclisiran: A Review in Hypercholesterolemia
inferred← citeshttps://doi.org/10.1007/s40256-024-00702-zopenalex-snapshot
A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran
inferred← citeshttps://doi.org/10.1007/s40256-024-00712-xopenalex-snapshot
Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future
inferred← citeshttps://doi.org/10.1007/s40256-025-00762-9openalex-snapshot
Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction
inferred← citeshttps://doi.org/10.1007/s40259-017-0220-yopenalex-snapshot
PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook
inferred← citeshttps://doi.org/10.1007/s40259-019-00399-6openalex-snapshot
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
inferred← citeshttps://doi.org/10.1007/s40262-025-01606-0openalex-snapshot
Platform Assessment of Concentration–QTc Relationship Across GalNAc–siRNA Molecules
inferred← citeshttps://doi.org/10.1007/s40265-017-0858-2openalex-snapshot
Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
inferred← citeshttps://doi.org/10.1007/s40265-019-01243-5openalex-snapshot
Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease
inferred← citeshttps://doi.org/10.1007/s40265-021-01473-6openalex-snapshot
Inclisiran: First Approval
inferred← citeshttps://doi.org/10.1007/s40265-025-02158-0openalex-snapshot
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
inferred← citeshttps://doi.org/10.1007/s40265-025-02173-1openalex-snapshot
The Potential of RNA Therapeutics in Treating Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/s40273-020-00948-wopenalex-snapshot
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
inferred← citeshttps://doi.org/10.1007/s40292-019-00306-8openalex-snapshot
Latest Updates on Lipid Management
inferred← citeshttps://doi.org/10.1007/s40292-019-00323-7openalex-snapshot
Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors
inferred← citeshttps://doi.org/10.1007/s40292-021-00501-6openalex-snapshot
Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension
inferred← citeshttps://doi.org/10.1007/s40292-024-00682-wopenalex-snapshot
Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials
inferred← citeshttps://doi.org/10.1007/s40495-019-00173-wopenalex-snapshot
Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines
inferred← citeshttps://doi.org/10.1007/s41969-022-00178-9openalex-snapshot
Stellenwert primärer Fettstoffwechselstörungen im Kontext aktueller Dyslipidämie-Leitlinien und aktueller Innovationen in der Lipidtherapie
inferred← citeshttps://doi.org/10.1007/s41975-022-00231-5openalex-snapshot
Individuelle kardiovaskuläre Risiken der Patientin in der Lebensmitte
inferred← citeshttps://doi.org/10.1007/s42000-018-0058-9openalex-snapshot
Lipids: a personal view of the past decade
inferred← citeshttps://doi.org/10.1016/b978-0-12-809356-6.00014-9openalex-snapshot
Genetic disorders of lipoprotein metabolism
inferred← citeshttps://doi.org/10.1016/b978-0-12-812535-9.00007-8openalex-snapshot
Lipoprotein and Lipid Metabolism
inferred← citeshttps://doi.org/10.1016/b978-0-12-814470-1.00003-4openalex-snapshot
Noncoding RNAs in Cardiovascular Disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-814470-1.00009-5openalex-snapshot
Controlling Protein Expression by Delivery of RNA Therapeutics Using Lipid Nanoparticles
inferred← citeshttps://doi.org/10.1016/b978-0-12-816861-5.00004-6openalex-snapshot
Diagnostics and Prevention: Landscape for Technology Innovation in Precision Cardiovascular Medicine
inferred← citeshttps://doi.org/10.1016/b978-0-12-818422-6.00030-7openalex-snapshot
Gene delivery into cells and tissues
inferred← citeshttps://doi.org/10.1016/b978-0-12-819869-8.00029-xopenalex-snapshot
Biomarkers in drug development
inferred← citeshttps://doi.org/10.1016/b978-0-12-820472-6.00014-1openalex-snapshot
Target Validation—Prosecuting the Target
inferred← citeshttps://doi.org/10.1016/b978-0-12-822258-4.00010-9openalex-snapshot
Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-823928-5.00041-4openalex-snapshot
Modulation of noncoding RNAs (ncRNAs) and their potential role as therapeutics
inferred← citeshttps://doi.org/10.1016/b978-0-323-85857-1.00036-5openalex-snapshot
Cholesterol and alcohol
inferred← citeshttps://doi.org/10.1016/b978-0-323-88286-6.00013-3openalex-snapshot
Treatment Guidelines Overview
inferred← citeshttps://doi.org/10.1016/b978-0-323-99991-5.00009-7openalex-snapshot
Proprotein convertase subtilisin kexin type 9 inhibitors and other novel lipid-modifying drugs: broadening the perspective of cardiovascular disease prevention
inferred← citeshttps://doi.org/10.1016/b978-0-44-313825-6.00329-0openalex-snapshot
Hypercholesterolemia
inferred← citeshttps://doi.org/10.1016/b978-0-443-15734-9.00001-7openalex-snapshot
Familial Hypercholesterolemia
inferred← citeshttps://doi.org/10.1016/b978-0-443-43986-5.00038-2openalex-snapshot
Therapeutic targets for cardiovascular diseases
inferred← citeshttps://doi.org/10.1016/bs.pmbts.2023.01.002openalex-snapshot
Epigenetics in cardiovascular health and disease
inferred← citeshttps://doi.org/10.1016/bs.pmbts.2024.01.004openalex-snapshot
RNA therapeutics history and future perspectives
inferred← citeshttps://doi.org/10.1016/bs.pmbts.2025.01.006openalex-snapshot
An introduction to non-coding RNAs
inferred← citeshttps://doi.org/10.1016/j.addr.2020.06.026openalex-snapshot
Lipid nanoparticle technology for therapeutic gene regulation in the liver
inferred← citeshttps://doi.org/10.1016/j.addr.2020.07.019openalex-snapshot
Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting
inferred← citeshttps://doi.org/10.1016/j.addr.2021.02.001openalex-snapshot
Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network
inferred← citeshttps://doi.org/10.1016/j.addr.2021.05.019openalex-snapshot
Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases
inferred← citeshttps://doi.org/10.1016/j.addr.2021.114041openalex-snapshot
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
inferred← citeshttps://doi.org/10.1016/j.ahj.2025.05.014openalex-snapshot
Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia
inferred← citeshttps://doi.org/10.1016/j.ahjo.2022.100127openalex-snapshot
Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies
inferred← citeshttps://doi.org/10.1016/j.ajpc.2022.100430openalex-snapshot
Earlier treatment in adults with high lifetime risk of cardiovascular diseases: What prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) Workshop
inferred← citeshttps://doi.org/10.1016/j.ajpc.2024.100639openalex-snapshot
Is there a role for earlier use of combination therapy?
inferred← citeshttps://doi.org/10.1016/j.ajpc.2024.100919openalex-snapshot
American society for preventive cardiology 2024 cardiovascular disease prevention: Highlights and key sessions
inferred← citeshttps://doi.org/10.1016/j.ajpc.2025.101265openalex-snapshot
Identification and management of patients at high-risk for cardiovascular disease in primary prevention
inferred← citeshttps://doi.org/10.1016/j.ajpc.2025.101314openalex-snapshot
The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease
inferred← citeshttps://doi.org/10.1016/j.ajpc.2026.101804openalex-snapshot
Rationale and design of the atrial natriuretic peptide and regulation of cardiometabolic health: a genotype-guided human physiological study (GENESIS)
inferred← citeshttps://doi.org/10.1016/j.amjcard.2018.06.023openalex-snapshot
Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9
inferred← citeshttps://doi.org/10.1016/j.amjcard.2020.05.024openalex-snapshot
A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Inclisiran
inferred← citeshttps://doi.org/10.1016/j.amjcard.2020.08.018openalex-snapshot
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
inferred← citeshttps://doi.org/10.1016/j.amjcard.2023.04.017openalex-snapshot
Role of Lipoprotein A in Lower Extremity Peripheral Artery Disease
inferred← citeshttps://doi.org/10.1016/j.amjcard.2025.04.013openalex-snapshot
The Impact of Inclisiran on Lipid Profiles in Adults with Hyperlipidemia: A Meta-Analysis and Meta-Regression of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1016/j.amjmed.2023.02.025openalex-snapshot
The Association Between PCSK9 Inhibitor Use and Sepsis: A Systematic Review and Meta-Analysis of 20 Double-Blind, Randomized, Placebo-Controlled Trials
inferred← citeshttps://doi.org/10.1016/j.apsb.2021.05.002openalex-snapshot
A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives
inferred← citeshttps://doi.org/10.1016/j.apsb.2022.06.011openalex-snapshot
Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia
inferred← citeshttps://doi.org/10.1016/j.apsb.2022.10.004openalex-snapshot
Lipid nanomaterials-based RNA therapy and cancer treatment
inferred← citeshttps://doi.org/10.1016/j.arcmed.2019.01.001openalex-snapshot
New and Future Parenteral Therapies for the Management of Lipid Disorders
inferred← citeshttps://doi.org/10.1016/j.artere.2025.100730openalex-snapshot
Efficacy, benefit and safety of inclisiran
inferred← citeshttps://doi.org/10.1016/j.arteri.2020.12.005openalex-snapshot
Dianas terapéuticas en el tratamiento de las dislipemias: de las estatinas a los inhibidores de PCSK9. Necesidades no cubiertas
inferred← citeshttps://doi.org/10.1016/j.arteri.2024.07.003openalex-snapshot
Eficacia, beneficio y seguridad de inclisiran
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2017.10.022openalex-snapshot
PCSK9 antagonists and inflammation
showing the first 200 of 988 · page through all 988
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.